Overview

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of gemcitabine/cisplatin alone.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Cisplatin
Gemcitabine